WSA
RVNC

Wall Street Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History

Wall Street Associates’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-57,330
Closed -$971K – 355
2014
Q4 		$971K Hold
57,330
– – 0.09% 205
2014
Q3 		$1.11M Sell
57,330
-24,680
-30% -$643K 0.11% 194
2014
Q2 		$2.79M Sell
82,010
-9,700
-11% -$304K 0.24% 130
2014
Q1 		$2.89M Buy
+91,710
New +$2.87M 0.24% 133

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wall Street Associates's RVNC Position: Q1 2015 in Review

Wall Street Associates sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2015, closing a stake of 57,330 shares — an estimated $971K sold.

Wall Street Associates first reported a position in RVNC in Q1 2014 and held it in 4 quarters. The position peaked at $2.89M in Q1 2014. 70 funds tracked by Wall St. Rank hold RVNC as of Q1 2015.

  • Wall Street Associates reported no remaining Revance Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Wall Street Associates sold 57,330 Revance Therapeutics, Inc. shares in Q1 2015, an estimated $971K.
  • Wall Street Associates first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Wall Street Associates's Revance Therapeutics, Inc. position peaked at $2.89M in Q1 2014.
  • 70 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2015.

Based on Wall Street Associates's 13F filing for Q1 2015, filed 14 May 2015.